Molecular Partners AG
3.00
CHF
-0.04
(-1.48%)
ISIN
CH0256379097
Return %
Stock
S&P 500
1Y
3.41
14.20
3Y
-16.63
81.12
5Y
-83.36
68.34
Capital Structure
CHF
•
in mil. unless spec.Working Capital
CHF
•
in mil. unless spec.Growth Rates
CHF
•
in mil. unless spec.Quarterly Revenue
CHF
•
in mil. unless spec.Quarterly Earnings Per Share
CHF
•
in mil. unless spec.Quarterly Dividends Per Share
CHF
•
in mil. unless spec.Company Description
- CEO
- Patrick Amstutz
- Full Time Employees
- 149
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Wagistrasse 14 Schlieren ZH Switzerland 8952
- IPO Date
- Nov 5, 2014
- Website
- molecularpartners.com
- Similar Companies
- Business
- Molecular Partners AG Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design, development and commercialization of DARPin therapeutics, a proprietary class of custom-built protein drugs engineered to address complex medical challenges in oncology, infectious diseases and other serious conditions that conventional modalities cannot readily treat; its core pipeline includes radiopharmaceuticals such as MP0712, a 212Pb-labeled DLL3-targeting agent for small cell lung cancer and neuroendocrine tumors, and MP0726, a 212Pb-labeled mesothelin-targeting agent for ovarian cancer; tetra-specific T cell engagers like MP0533 targeting CD33 x CD123 x CD70 x CD3 for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes; tumor-localized immune activators including MP0317, a FAP x CD40 agonist for advanced solid tumors; next-generation immune cell engagers such as MP0621, a cKit x CD16a x CD47 Switch-DARPin for hematopoietic stem cell conditioning; and antiviral candidates like ensovibep, a tri-specific DARPin against SARS-CoV-2 for COVID-19. The company operates primarily in Switzerland and the United States, with additional focus on global markets through partnerships, targeting patients with high-unmet-need cancers, hematologic malignancies and infectious diseases. Founded in 2004 and headquartered in Schlieren, Switzerland, with offices in Cambridge and Concord, Massachusetts, USA, Molecular Partners AG maintains a robust cash position of CHF 114 million as of June 30, 2025, funding operations into 2028. In January 2025, it expanded its strategic global collaboration with Orano Med from four to up to ten targeted alpha therapy programs using 212Pb payloads, encompassing lead candidates MP0712 and MP0726, with Orano Med providing isotope production and manufacturing for clinical trials and commercialization; the company completed its data package for MP0712's investigational new drug application, anticipating filing and Phase 1 trial initiation in 2025 alongside initial human data in the first half of 2026. Recent advancements include updated Phase 1/2a data for MP0533 showing improved response rates and depths in dosing cohort 8, with cohort 9 enrollment underway and further results expected in 2025; in June 2025, Molecular Partners announced operational efficiencies including a 24% workforce reduction to extend cash runway, with full implementation by year-end and cost savings effective in early 2026; it also completed a USD 20 million underwritten offering of American Depositary Shares in October 2024 and presented new preclinical data for MP0712 at the TRP Summit Europe 2025 in November, highlighting initial human imaging and mechanism of action.
Company News
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting